While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Bernstein analyst Courtney Breen maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $380.00.

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...

Me CEO Anne Wojcicki continues to maintain a strong outlook despite recent high-profile stumbles. “We are a long-term company ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

That may have changed with a new court decision that favored Amgen (NASDAQ: AMGN), the maker of Pavblu. Regeneron failed to convince a judge to issue a preliminary injunction (a temporary court ...

The big blow came Monday after a court ruling raised the possibility of Amgen Inc. launching a copycat ... injunction against Amgen’s drug, Pavblu. The decision “creates uncertainty about ...